Related news from
Mon, 20 Apr 2026 04:18:19 +0000	Cencora Retina Deal Deepens Specialty Eye Care And Earnings Story Cencora (NYSE:COR) has agreed to acquire the retina business of EyeSouth Partners. The deal expands Cencora's specialty eye care operations and broadens its clinical network. The transaction focuses on retina services, a key area within ophthalmology care. Cencora operates as a pharmaceutical solutions organization with a focus on specialty distribution and services, and the move into EyeSouth Partners' retina business fits within that profile. Specialty eye care sits at the intersection of...
Fri, 17 Apr 2026 07:36:56 +0000	What You Need to Know Ahead of Cencora's Earnings Release Cencora is scheduled to report its second-quarter results next month, and analysts project a single-digit increase in earnings.
Mon, 13 Apr 2026 08:04:47 +0000	Assessing Cencora (COR) Valuation As Short Term Momentum Cools And Long Term Returns Remain Strong Cencora (COR) has been drawing attention after recent share price volatility, with the stock down about 8% over the past month and roughly 7% over the past 3 months from its last close of $320.82. See our latest analysis for Cencora. Despite the recent weak patch in the share price, with a 30 day share price return of 8.32% and 90 day share price return of 7.25%, longer term total shareholder returns of 13.66% over 1 year and 183.05% over 5 years show that investors who stayed invested have...
Mon, 06 Apr 2026 12:53:20 +0000	Is Medline Inc. (MDLN) A Good Stock To Buy Now? Is MDLN a good stock to buy? We came across a bullish thesis on Medline Inc. on The Pursuit of Compounding’s Substack. In this article, we will summarize the bulls’ thesis on MDLN. Medline Inc.’s share was trading at $41.36 as of March 27th. MDLN’s trailing and forward P/E were 29.91 and 29.24 respectively according to Yahoo Finance. Medline Industries (MDLN) […]
Thu, 02 Apr 2026 14:00:20 +0000	2 S&P 500 Stocks with Exciting Potential and 1 We Ignore The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Wed, 01 Apr 2026 14:27:00 +0000	Can CAH's Specialty Flywheel Strategy Unlock Long-Term Growth? CAH's specialty flywheel strategy links distribution, MSOs and biopharma services, boosting partnerships, drug launches and recurring revenue potential.
Tue, 31 Mar 2026 10:21:19 +0000	1 Large-Cap Stock for Long-Term Investors and 2 We Avoid Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
Tue, 31 Mar 2026 05:03:35 +0000	Is It Time To Reassess Cencora (COR) After The Recent Share Price Pullback? Investors may be wondering whether Cencora is attractively priced after its recent run and pullback, or if the stock is now reflecting too much optimism. The share price closed at US$309.93, with a 3.3% decline over the last 7 days and a 16.7% decline over the last 30 days. This is set against a 12.2% return over 1 year and very strong returns over 3 and 5 years. Recent coverage has focused on Cencora as a key healthcare distributor and supply chain player, with attention on how it fits into...
Mon, 30 Mar 2026 11:39:57 +0000	Cencora, Inc. (COR) Signs Binding Agreement to Expand Retina Network With EyeSouth Acquisition We recently compiled a list of the 13 Best Stocks to Invest In on Robinhood for Beginners. Cencora, Inc. is the next best Robinhood stock on this list. TheFly reported on March 23 that COR revealed that it has signed a binding agreement to acquire the retina division of EyeSouth Partners for $1.1 billion. Once the […]
Thu, 26 Mar 2026 14:57:21 +0000	Reflecting On Health Insurance Providers Stocks’ Q4 Earnings: Cencora (NYSE:COR) As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at health insurance providers stocks, starting with Cencora (NYSE:COR).
Wed, 25 Mar 2026 02:34:22 +0000	Why STAAR Surgical (STAA) Stock Is Trading Up Today Shares of medical lens company STAAR Surgical (NASDAQ:STAA) jumped 3.7% in the afternoon session after investors reacted to positive news in the broader ophthalmology sector as Cencora agreed to acquire EyeSouth Partners' retina business for $1.1 billion.
Tue, 24 Mar 2026 14:21:00 +0000	COR to Expand Retina Consultants of America With $1.1B EyeSouth Deal Cencora is acquiring EyeSouth's retina business for $1.1 billion, expanding its RCA platform to strengthen foothold in the fast-growing eye care market.
Tue, 24 Mar 2026 09:19:42 +0000	Cencora to buy EyeSouth’s retina business for $1.1B The proposed acquisition is Cencora’s latest push into retina services as the company looks to expand its specialty support business. Cencora doesn't expect the deal to close before the end of September.
Sun, 22 Mar 2026 16:05:06 +0000	Cencora CFO Retirement Puts Capital Allocation And Growth Plans In Focus Cencora (NYSE:COR) announced the planned retirement of Chief Financial Officer and Executive Vice President James F. Cleary. The company has begun a leadership transition process and initiated an executive search to identify his successor. Cleary’s retirement marks the end of a long tenure in the CFO role and a significant change in Cencora’s senior leadership team. Cencora, a major player in pharmaceutical distribution and related services, sits at the center of global drug supply chains,...
Fri, 20 Mar 2026 13:25:05 +0000	Here’s Why Cencora (COR) Shares Rose 8% in Q4 TimesSquare Capital Management, an equity investment management company, released its “U.S. Focus Growth Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The strategy returned -3.55% (gross) and -3.76% (net) in the fourth quarter compared to a -3.70% return for the Russell Midcap Growth Index. In 2025, the strategy returned 14.84% […]
Wed, 18 Mar 2026 11:13:35 +0000	1 Healthcare Stock with Exciting Potential and 2 We Ignore From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 3.6% over the past six months, topping the S&P 500 by 2.3 percentage points.
Tue, 17 Mar 2026 17:06:00 +0000	Here's Why You Should Hold Cencora Stock in Your Portfolio for Now Cencora's strong U.S. growth, MSO strategy, and raised outlook support long-term potential, but competition and customer losses remain key risks.
Tue, 17 Mar 2026 09:32:18 +0000	Cencora CFO announces retirement James Cleary will step down from the post on June 30, but stay on as an adviser to the company through the end of the year. He’s the second finance chief of a drug distributor to announce their retirement this month.
Fri, 13 Mar 2026 15:30:05 +0000	Why Is Avantor (AVTR) Down 13.6% Since Last Earnings Report? Avantor (AVTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Fri, 13 Mar 2026 13:57:00 +0000	CAH's Pharma Segment Gains 19% in Q2'26: Is the Growth Sustainable? CAH's Pharmaceutical and Specialty Solutions segment surged in fiscal Q2'26 with 19% revenue growth to $61B, fueled by specialty drugs, GLP-1 demand and generics momentum.

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like REITs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!